The actions of glutamate as both an excitatory neurotransmitter and a potent neurotoxin necessitate that its concentrations within CNS be carefully regulated. High affinity glutamate transporters are believed to play a key role in maintaining the balance between these physiological and pathological processes. The rapid clearance of glutamate through these uptake systems and into neurons and glia is postulated to contribute to signal termination, transmitter recycling, and the maintenance of extracellular glutamate levels below those that can induce excitotoxic damage. In view of these protective roles, it is ironic that the reversed action of these systems under pathological conditions may actually increase extracellular glutamate levels and contribute to the induction of excitotoxic neuronal injury. The goal of this proposal continues to be a detailed biochemical characterization of the excitatory amino acid uptake systems. The experiments are designed to elucidate the pharmacological and kinetic properties that distinguish each of the glutamate transporters. Particular emphasis is placed on the use of conformationally constrained glutamate analogues to define their individual pharmacophores and generate a library of selective substrates and inhibitors. Experiments will be carried out with cells lines stably expressing each of the four identified human sodium dependent transporter subtypes (EAAT1, EAAT2, EAAT3, and EAAT4). As considerable progress has already been made in delineating the specificity of the EAAT2 subtype, studies on this transporter will focus on the development of photoaffinity inhibitors. Studies of uptake system heterogeneity will also be extended to include two sodium independent systems: one that is present on synaptic vesicles and a chloride dependent glial system. The end result of these investigations will be a series of well defined inhibitors and substrates that can be used to selectively study and modify transporter activity. In a final series of experiment, these inhibitors will be used to vary uptake activity and elucidate the role of transport in both protecting neurons from excitotoxic injury and as a source of extracellular glutamate under pathological conditions. Overall, the results of this project will provide significant insight into the properties of the excitatory amino acid transport systems and their ability to regulate the physiological and pathological levels of glutamate in the CNS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS030570-07
Application #
2891833
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Talley, Edmund M
Project Start
1992-12-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Montana
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
City
Missoula
State
MT
Country
United States
Zip Code
59812
Ahmed, S Kaleem; Etoga, Jean-Louis G; Patel, Sarjubhai A et al. (2011) Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-). Bioorg Med Chem Lett 21:4358-62
Etoga, Jean-Louis G; Ahmed, S Kaleem; Patel, Sarjubhai et al. (2010) Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter. Bioorg Med Chem Lett 20:2680-3
Patel, Sarjubhai A; Rajale, Trideep; O'Brien, Erin et al. (2010) Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model. Bioorg Med Chem 18:202-13
Ye, Ran; Rhoderick, Joseph F; Thompson, Charles M et al. (2010) Functional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2. Protein Expr Purif 74:49-59
Mavencamp, Terri L; Rhoderick, Joseph F; Bridges, Richard J et al. (2008) Synthesis and preliminary pharmacological evaluation of novel derivatives of L-beta-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3. Bioorg Med Chem 16:7740-8
Queen, Susan A; Kesslak, J Patrick; Bridges, Richard J (2007) Regional distribution of sodium-dependent excitatory amino acid transporters in rat spinal cord. J Spinal Cord Med 30:263-71
Bridges, Richard J; Esslinger, C Sean (2005) The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 107:271-85
Esslinger, C Sean; Agarwal, Shailesh; Gerdes, John et al. (2005) The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology 49:850-61
Patel, Sarjubhai A; Warren, Brady A; Rhoderick, Joseph F et al. (2004) Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46:273-84
Warren, Brady A; Patel, Sarjubhai A; Nunn, Peter B et al. (2004) The Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid is a substrate of the L-cystine/L-glutamate exchanger system xc-. Toxicol Appl Pharmacol 200:83-92

Showing the most recent 10 out of 24 publications